Bioxel Pharma Inc. (TSX VENTURE:BIP), a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, announces that the Corporation has begun delivery of paclitaxel to a leading European generic products company under terms of the manufacturing and supply agreement executed between the parties on February 23, 2006. The sale of paclitaxel to this new business partner is expected to yield revenues of approximately $800,000 in 2006.
